The effects of progesterone and progestins on endometrial proliferation

Contraception

Volumn 57, Issue 6, 1998, Pages 399-403

  Moyer, Dean L ^a   Felix, Juan Carlos ^b  

^a NovaMed Laboratory   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Endometrium; Hormone replacement therapy; Progesterone; Progestin

Indexed keywords

CYCLIN B; CYCLINE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY KI 67; NORETHISTERONE ACETATE; NORETYNODREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CYTOLOGY; FEMALE; FOLLICULAR PHASE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MITOSIS INDEX; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE;

AMERICAS; BIOLOGY; CLINICAL RESEARCH; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; ENDOMETRIAL EFFECTS; ENDOMETRIUM; ESTROGENS--SIDE EFFECTS; GENITALIA; GENITALIA, FEMALE; HORMONE REPLACEMENT THERAPY; HORMONES; MENOPAUSE; NORTH AMERICA; NORTHERN AMERICA; PHYSIOLOGY; PROGESTATIONAL HORMONES; PROGESTERONE--BENEFICIAL EFFECTS; REPRODUCTION; RESEARCH METHODOLOGY; RESEARCH REPORT; TREATMENT; UNITED STATES; UROGENITAL SYSTEM; UTERUS;

ATROPHY; BIOPSY; CELL DIVISION; CONTRACEPTIVES, ORAL; CYCLINS; ENDOMETRIUM; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MESTRANOL; MIDDLE AGED; MITOSIS; NORETHINDRONE; NORETHYNODREL; POSTMENOPAUSE; PREMENOPAUSE; PROGESTERONE CONGENERS; PROLIFERATING CELL NUCLEAR ANTIGEN; STROMAL CELLS;

EID: 0031853941     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(98)00047-X     Document Type: Article

References (20)

1. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol. 69:1987;929-932.
2. Lobo R.A. The role of progestins in hormone replacement therapy. Am J Obstet Gynecol. 166:1992;1997-2004.
3. Paterson M.E.L., Wade-Evans T., Sturdee D.W., et al. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J. 280:1980;822-824.
4. Woodruff JD, Pickar JH, for The Menopause Study Group. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170:1213-23.
5. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
6. Ettinger B., Golditch I.M., Friedman G. Gynecologic consequences of long-term unopposed estrogen replacement therapy. Maturitas. 10:1988;271-282.
7. Paganini-Hill A., Ross R.K., Henderson B.F. Endometrial cancer and patterns of use of oestrogen replacement therapy a cohort study . Br J Cancer. 59:1989;445-447.
8. Gambrell R.D. Prevention of endometrial cancer with progestogens. Maturitas. 8:1986;159-168.
9. Oral contaceptive use and the risk of endometrial cancer. JAMA. 249:1983;1600-1604.
10. Endometrial cancer and combined oral contraceptives the WHO Collaborative Study of Neoplasia and Steriod Contraceptives . Int J Epidemiol. 17:1988;263-269.
11. Moyer D.L., de Lignieres D., Driguez P., et al. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement influence of bleeding pattern and secretory changes . Fertil Steril. 59:1993;992-997.
12. Felix J.C., Farahmand S. Endometrial glandular proliferation and estrogen receptor content during the normal menstrual cycle. Contraception. 55:1997;19-22.
13. Noyes R.W., Hertig A.T., Rock J. Dating the endometrial biopsy. Fertil Steril. 1:1955;3-25.
14. Shi S.R., Iman S.A., Young L., et al. Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem. 43:1995;193-201.
15. Dutta A., Chandra R., Leiter L.M., et al. Cyclins as markers of tumor proliferation. Immunochemical studies. Proc Natl Acad Sci. 92:1995;5386-5390.
16. Shi S.R., Chaiwun B., Young L., et al. Antigen retrieval using pH 3.5 glycine-HCl localization of K167. Biotech Histochem. 69:1994;213-215.
17. Stanczyk F.Z. Structure-function relationships, potency and pharmacokinetics of progestogens. Lobo R.A. Treatment of the Postmenopausal Woman, Basic and Clinical Aspects. 1994;Raven Press, New York.
18. King R.J.B., Whitehead M.I. Assessment of the potency of orally administered progestins in women. Fertil Steril. 46:1986;1062-1066.
19. Gibbons W.E., Moyer D.L., Lobo R.A., et al. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol. 154:1986;456-461.
20. Mishell D.R. Jr, Shoupe D., Moyer D.L., et al. Postmenopausal hormone replacement with a combination estrogen-progestin regimen for five days per week. J Reprod Med. 36:1991;351-355.